Phaseline

Companies › SpectraCure

SpectraCure: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Verteporfin
Photosensitizer for photodynamic therapy
–Phase 1Recurrent Prostate Cancer; Prostate Cancer; Surgical Scar; Malignant Solid NeoplasmJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03067051VerteporfinPhase 1Recurrent Prostate CancerOncologyJul 2027
NCT06807359VerteporfinPhase 1Prostate CancerOncologyJan 2028
NCT07488988VerteporfinPhase 2Surgical ScarOtherAug 2028
NCT06306638VerteporfinPhase 1Malignant Solid NeoplasmOncologyOct 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.